Logan Coy Related postsA Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after OsimertinibSeptember 11, 2026Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)September 11, 2026A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin LymphomaSeptember 11, 2026 Previous postA First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Advanced Solid TumorsNext postAn Open-Label, Multicenter, Multi-Arm Phase 1 Study of ADU-1805 in Adults with Advanced Solid Tumors